首页 | 本学科首页   官方微博 | 高级检索  
检索        

抗高尿酸血症药物研究进展
引用本文:刘永贵,赵丽嘉,崔艳丽,贺星,沈雪砚,陈常青.抗高尿酸血症药物研究进展[J].现代药物与临床,2015,30(3):345-350.
作者姓名:刘永贵  赵丽嘉  崔艳丽  贺星  沈雪砚  陈常青
作者单位:天津药物研究院 医药信息中心,天津,300193
摘    要:痛风是一种代谢性疾病,危害严重,近年来患病率呈上升趋势。尿酸排泄减少或生成增多所致的高尿酸血症是痛风的主要病因,而高尿酸又与多种疾病密切相关。降低血尿酸水平是治疗痛风,预防痛风复发的重要措施。目前,抗高尿酸血症药物主要有3类,分别是黄嘌呤氧化酶抑制剂、尿酸盐阴离子转运蛋白1(URAT1)抑制剂和尿酸氧化酶类似物。对现有抗高尿酸血症药物的现状以及研究进展进行总结,希望对其研发提供参考。

关 键 词:痛风  高尿酸血症  抗高尿酸血症药  黄嘌呤氧化酶抑制剂  URAT1抑制剂  尿酸氧化酶
收稿时间:1/7/2015 12:00:00 AM

Research progress on anti-hyperuricemic drugs
LIU Yong-gui,ZHAO Li-ji,CUI Yan-li,HE Xing,SHEN Xue-yan and CHEN Chang-qing.Research progress on anti-hyperuricemic drugs[J].Drugs & Clinic,2015,30(3):345-350.
Authors:LIU Yong-gui  ZHAO Li-ji  CUI Yan-li  HE Xing  SHEN Xue-yan and CHEN Chang-qing
Institution:Centre of Pharmaceutical Information, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China;Centre of Pharmaceutical Information, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China;Centre of Pharmaceutical Information, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China;Centre of Pharmaceutical Information, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China;Centre of Pharmaceutical Information, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China;Centre of Pharmaceutical Information, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China
Abstract:Gout is a metabolic disease, and does serious harm to human beings. In recent years, gout prevalence rate assumes upwards trend. Hyperuricemia caused by decreased uric acid excretion or increased formation of uric acid may account for gout. While high uric acid is closely related to various diseases. Therefore reducing blood uric acid level is the important measure to treat gout and prevent the recurrence of gout. So far, there are three kinds of anti-hyperuricemic drugs, including xanthine oxidase inhibitors, Urate anion exchanger 1 (URAT1) inhibitors, and urate oxidase analogues. The present situation and research progress of anti-hyperuricemic drugs are reviewed in this paper, in order to provide a reference for the development of anti-hyperuricemic drugs.
Keywords:gout  hyperuricemia  anti-hyperuricemic drugs  xanthine oxidase inhibitors  URAT1 inhibitors  urate oxidase
本文献已被 CNKI 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号